Stock Track | GeneDx Holdings Soars 5.15% Intraday After Q4 Earnings and Revenue Beat Estimates

Stock Track02-24

GeneDx Holdings Corp. (WGS) saw its stock price surge 5.15% during intraday trading on Monday. The significant upward movement followed the release of the company's fourth-quarter and full-year 2025 financial results.

The genetic testing company reported quarterly adjusted earnings of $0.14 per share, surpassing the analyst consensus estimate of $0.11. Revenue for the quarter reached $121 million, also beating expectations and marking a 26.5% increase year-over-year. A key growth driver was a 32% year-over-year rise in revenue from exome and genome tests, with test volumes growing 34.3%.

Further bolstering investor confidence, the company reaffirmed its full-year 2026 revenue guidance of $540 million to $555 million, which is above the current analyst consensus. The guidance anticipates 33% to 35% growth in its core exome and genome test revenue. Analysts maintain a positive outlook on the stock, with a consensus "buy" rating and a median 12-month price target significantly above recent trading levels.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1191617616?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-24 02:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1191617616","market":"sg","top_or_hot":-1,"title":"Stock Track | GeneDx Holdings Soars 5.15% Intraday After Q4 Earnings and Revenue Beat Estimates","media":"Stock Track","content":"<p>GeneDx Holdings Corp. (WGS) saw its stock price surge 5.15% during intraday trading on Monday. The significant upward movement followed the release of the company's fourth-quarter and full-year 2025 financial results.</p><p>The genetic testing company reported quarterly adjusted earnings of $0.14 per share, surpassing the analyst consensus estimate of $0.11. Revenue for the quarter reached $121 million, also beating expectations and marking a 26.5% increase year-over-year. A key growth driver was a 32% year-over-year rise in revenue from exome and genome tests, with test volumes growing 34.3%.</p><p>Further bolstering investor confidence, the company reaffirmed its full-year 2026 revenue guidance of $540 million to $555 million, which is above the current analyst consensus. The guidance anticipates 33% to 35% growth in its core exome and genome test revenue. Analysts maintain a positive outlook on the stock, with a consensus \"buy\" rating and a median 12-month price target significantly above recent trading levels.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | GeneDx Holdings Soars 5.15% Intraday After Q4 Earnings and Revenue Beat Estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | GeneDx Holdings Soars 5.15% Intraday After Q4 Earnings and Revenue Beat Estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-24 02:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>GeneDx Holdings Corp. (WGS) saw its stock price surge 5.15% during intraday trading on Monday. The significant upward movement followed the release of the company's fourth-quarter and full-year 2025 financial results.</p><p>The genetic testing company reported quarterly adjusted earnings of $0.14 per share, surpassing the analyst consensus estimate of $0.11. Revenue for the quarter reached $121 million, also beating expectations and marking a 26.5% increase year-over-year. A key growth driver was a 32% year-over-year rise in revenue from exome and genome tests, with test volumes growing 34.3%.</p><p>Further bolstering investor confidence, the company reaffirmed its full-year 2026 revenue guidance of $540 million to $555 million, which is above the current analyst consensus. The guidance anticipates 33% to 35% growth in its core exome and genome test revenue. Analysts maintain a positive outlook on the stock, with a consensus \"buy\" rating and a median 12-month price target significantly above recent trading levels.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"WGS","symbol_name":"GeneDx Holdings","start_time":0,"source_url":"","article_id":"1191617616","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1191617616","pubTimestamp":1771871836,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"GeneDx Holdings Corp. (WGS) saw its stock price surge 5.15% during intraday trading on Monday. The significant upward movement followed the release of the company's fourth-quarter and full-year 2025...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"WGS":"GeneDx Holdings"},"translate_title":"个股追踪|GeneDx Holdings盘中大涨5.15%Q4盈利营收超预期","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"WGS":1},"content_text":"GeneDx Holdings Corp. (WGS) saw its stock price surge 5.15% during intraday trading on Monday. The significant upward movement followed the release of the company's fourth-quarter and full-year 2025 financial results.The genetic testing company reported quarterly adjusted earnings of $0.14 per share, surpassing the analyst consensus estimate of $0.11. Revenue for the quarter reached $121 million, also beating expectations and marking a 26.5% increase year-over-year. A key growth driver was a 32% year-over-year rise in revenue from exome and genome tests, with test volumes growing 34.3%.Further bolstering investor confidence, the company reaffirmed its full-year 2026 revenue guidance of $540 million to $555 million, which is above the current analyst consensus. The guidance anticipates 33% to 35% growth in its core exome and genome test revenue. Analysts maintain a positive outlook on the stock, with a consensus \"buy\" rating and a median 12-month price target significantly above recent trading levels.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1191617616","isCrawlerRequest":true}